Final OS analysis of ICARIA-MM: Isatuximab triplet shows continued survival benefit in R/R multiple myeloma

Share :
Published: 12 Oct 2022
Views: 3021
Dr Paul Richardson - Dana Farber Cancer Institue, Boston, USA

Dr Paul Richardson speaks to ecancer about the ICARIA-MM final overall survival analysis. Isatuximab-irfc plus pomalidomide and low-dose dexamethasone (Isa-Pd) continues to show clinically meaningful benefit for patients with relapsed or refractory multiple myeloma demonstrating an improved overall survival (OS) over pomalidomide alone.

At a median follow-up of 35.3 months, the median OS was 24.6 months in the isatuximab group vs 17.7 months in the Pd group. Overall, there were 220 OS events with 106 in the Isa-Pd arm and 114 in the Pd arm.

Dr Richardson explains that the final analysis of this study also examined the impact of the Isa-PD treatment in the real world by observing deaths due to COVID-19.

These findings were presented at the 19th International Myeloma Society annual meeting, where researchers found that COVID-19 negatively impacted the overall survival of the Isa-Pd arm.

He concludes by talking about the clinical value of these results.

ecancer's filming has been kindly supported by Sanofi through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.